Fintel reports that on August 15, 2023, Needham reiterated coverage of Clearside Biomedical (NASDAQ:CLSD) with a Buy recommendation.
Analyst Price Forecast Suggests 483.84% Upside
As of August 2, 2023, the average one-year price target for Clearside Biomedical is 5.78. The forecasts range from a low of 4.04 to a high of $8.40. The average price target represents an increase of 483.84% from its latest reported closing price of 0.99.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Clearside Biomedical is 2MM, an increase of 50.74%. The projected annual non-GAAP EPS is -0.60.
What is the Fund Sentiment?
There are 78 funds or institutions reporting positions in Clearside Biomedical. This is a decrease of 4 owner(s) or 4.88% in the last quarter. Average portfolio weight of all funds dedicated to CLSD is 0.01%, a decrease of 6.21%. Total shares owned by institutions decreased in the last three months by 3.47% to 8,941K shares. 
The put/call ratio of CLSD is 0.42, indicating a bullish outlook.
What are Other Shareholders Doing?
Carmignac Gestion holds 2,400K shares representing 3.89% ownership of the company. No change in the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,384K shares representing 2.24% ownership of the company. No change in the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 698K shares representing 1.13% ownership of the company. No change in the last quarter.
Geode Capital Management holds 530K shares representing 0.86% ownership of the company. No change in the last quarter.
Renaissance Technologies holds 337K shares representing 0.55% ownership of the company. In it's prior filing, the firm reported owning 459K shares, representing a decrease of 36.44%. The firm decreased its portfolio allocation in CLSD by 14.35% over the last quarter.
Clearside Biomedical Background Information
(This description is provided by the company.)
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company's SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications.
Additional reading:
- CLEARSIDE BIOMEDICAL, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement
- CLEARSIDE BIOMEDICAL, INC., Dated as of [•], 20___ Debt Securities
- CLEARSIDE BIOMEDICAL, INC. , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF
- CLEARSIDE BIOMEDICAL, INC. _________________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________
- CLEARSIDE BIOMEDICAL, INC. , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
